DiNAQOR

Executive Summary

DiNAQOR AG is a Swiss health technology company builder founded in 2019, focused on creating and scaling next-generation biotechnology ventures in RNA & gene therapy and viral vector technology. The company leverages deep expertise in early-stage drug development to advance novel therapies from discovery through preclinical proof-of-concept, with the goal of partnering or spinning out programs. By combining a platform approach with strategic collaborations, DiNAQOR aims to de-risk development and accelerate the translation of scientific innovations into clinical candidates. While still private and early-stage, the company's differentiated model positions it to capture value in the rapidly growing gene therapy space. Near-term value inflection points could come from new venture creation, platform partnerships, and preclinical data milestones.

Upcoming Catalysts (preview)

• TBDAnnouncement of a new spin-out venture targeting a genetic disease70% success
• TBDPartnership or licensing deal for viral vector platform with a major pharma60% success
• TBDRelease of preclinical proof-of-concept data for lead gene therapy program80% success